Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Bilirubin can inhibit clogging of arteries and prevent deadly consequences

Each year, about 610,000 Americans suffer their first heart attack, according to the Centers for Disease Control and Prevention. Heart attacks and other symptoms of cardiovascular disease can be caused when blockage occurs in the arteries. In a new study from the University of Missouri, a scientist has discovered a natural defense against arterial blockage: bilirubin.

6 Dec 2012

Sorin Group’s Mitroflow valve receives Japanese PMDA approval

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it received the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval for the Mitroflow Aortic Pericardial Heart Valve.

4 Dec 2012

GORE EXCLUDER AAA Endoprosthesis receives CE Mark

W. L. Gore & Associates, Inc. (Gore) has received CE Mark for the new large diameter 35 mm trunk-ipsilateral leg and 36 mm aortic extender components of the GORE EXCLUDER AAA Endoprosthesis.

3 Dec 2012

Heart attack centres: an interview with Dr Sayan Sen

Heart attack networks are designed to facilitate the rapid transfer of heart attack patients to centres with facilities that allow the manual unblocking of the coronary artery with angioplasty.

3 Dec 2012

Enrollment complete in Tryton's Pivotal IDE Side Branch Stent trial to treat bifurcation lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the completion of enrollment in the TRYTON Pivotal IDE trial evaluating the Tryton Side Branch Stent.

26 Nov 2012

St. Jude Medical’s Portico transcatheter heart valve receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval for its 23 mm Portico Transcatheter Aortic Heart Valve and Transfemoral Delivery System.

20 Nov 2012

FDA approves Cook's Zilver PTX drug-eluting peripheral stent

Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.

16 Nov 2012

Cook receives FDA approval for Zilver PTX Drug-Eluting Peripheral Stent to treat PAD

The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked as a result of peripheral artery disease (PAD).

15 Nov 2012

Antibody-coated stents carry increased risk of myocardial infarction and re-operation

If narrowed or blocked coronary vessels have to be widened or opened, a vascular support (stent) is usually inserted. Drug-coated stents are preferred for patients at high risk of renewed narrowing of vessels (restenosis). However, the use of antibody-coated stents has been increasing in recent years. Current studies provide indications that these new antibody-coated stents more frequently lead to myocardial infarction and make re-operation necessary.

15 Nov 2012

Mini-stent shows promising glaucoma control

The implantation of a microstent into the eyes of patients with open-angle glaucoma could remove their need to use eye drops to reduce intraocular pressure, show the 1-year results of a clinical trial.

14 Nov 2012

Hydrus stent may significantly reduce eye pressure in glaucoma patients

A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, according to year-one clinical trial results for the device.

14 Nov 2012

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine.

7 Nov 2012

Study compares effectiveness of CABG surgery with PCI for adults with diabetes and heart disease

Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study. The research was supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

5 Nov 2012

Blue Medical’s drug eluting balloon Protégé receives CE mark

Blue Medical, the global medical device company and innovator in the treatment of vascular diseases, today announced receiving the CE mark for Protégé NC, a non compliant drug eluting balloon.

30 Oct 2012

Drug-eluting stents exhibit some benefits in patients over 80

Rarely tested in patients over the age of 80, a study found that drug-eluting stents exhibited some benefits over bare-metal stents, though both types of stents demonstrated a clinical benefit. Results of the XIMA trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

29 Oct 2012

Mesh-covered stent improves restoration of blood flow after PCI in heart attack patients

A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty.

25 Oct 2012

Combining distal protection devices with nicardipine improves post-PCI outcomes

Researchers at Thomas Jefferson University Hospital have shown that combining distal protection devices with the prophylactic use of the drug nicardipine is more effective at preventing life-threatening complications following a percutaneous coronary intervention (PCI) (angioplasty, stenting) on patients who have undergone previous bypass surgery than distal protection devices alone.

23 Oct 2012

Drug-eluting balloon procedure can effectively treat peripheral artery disease

Use of balloon angioplasty and placement of stents to widen clogged arteries have become standard medical procedure. Further advancing this treatment, drug-eluting devices are now delivering medication directly to the site where it can be most effective. While this technique has met with success in coronary arteries, its use in peripheral arteries is still under study.

16 Oct 2012

Final results from Covidien’s DEFINITIVE LE study on peripheral arterial disease

Covidien, a leading global provider of healthcare products, today announced final 12-month results from its DEFINITIVE LE (Determination of Effectiveness of SilverHawk / TurboHawk Peripheral Plaque Excision Systems for the Treatment of Infrainguinal Vessels/Lower Extremities) study.

11 Oct 2012

Boston Scientific initiates enrollment in Lotus Valve System clinical trial for aortic valve disease

Boston Scientific has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus Valve System in up to 120 patients with severe aortic valve disease.

10 Oct 2012